INCRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Intercure Ltd.
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 30, 2026
$4.46−0.11 (-2.41%)
Close on Oct 19, 2026
Intercure Ltd. revenue by segment
By business segment
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|
| Reportable segments [member] | 270.20M ILS | 238.85M ILS | 355.55M ILS | 388.68M ILS | 219.68M ILS | 65.04M ILS | – | 100.0% | +13.1% |
| Cannabis segment [member] | 270.20M ILS | 238.85M ILS | 355.55M ILS | 388.68M ILS | 219.68M ILS | 65.04M ILS | 9.61M ILS | 100.0% | +13.1% |
| Reconciliations [member] | – | – | – | – | – | – | -683.00K ILS | – | – |
By product or service
By region
From the segment and revenue-disaggregation notes of Intercure's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.